KM Management spol. s r.o. — Clinical Trial Site

24 Registered trials

8 Currently recruiting

Organisation

KM Management spol. s r.o.

Location

Nitra, Slovakia

Identifier

ORG-100045795

Address

Spitalska 13, Stare Mesto, 949 01, Slovakia

Departments

-
Ambulance of Gastroenterology
Ambulancia pediatrickej gastroenterologie, hepatologie a vyzivy
Gastoenterologicka ambulancia
Gastroenterológia
Gastroenterologicka ambulancia
Gastroenterologicke a hepatologicke centrum
gastroenterology
Gastrologická ambulancia
KM Management spol. s.r.o. (#1)
NA
SK10004, Gastroenterologicka ambulancia

Clinical trials at this site (24)

Search interface

A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
A Study of how the Medicine Called "Etrasimod" Works in Children With the gut Disease Called Ulcerative Colitis Recruiting

2025-523100-77-00 Ulcerative Colitis 4 2026-04-23
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn'… Recruiting

2024-513054-30-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c… Recruiting

2023-504265-23-00 Crohn's disease 4 2023-10-23
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis Recruiting

2022-500345-25-00 Moderately to severely active ulcerative colitis 4 2023-01-16
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended

2024-518998-33-00 Ulcerative Colitis 5 2025-07-23
A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat… Ended

2024-513015-27-00 Moderately to Severely Active Ulcerative Colitis (UC) 5 2025-01-09
A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended

2023-510487-12-00 Crohn's Disease 4 2024-11-29
Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended

2023-504040-34-01 Crohn’s Disease 5 2024-11-12
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended

2022-500290-14-01 Colitis ulcerative 4 2023-05-11
A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended

2022-501645-70-00 Crohns Disease 5 2020-11-25
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended

2023-506994-36-00 Ulcerative Colitis 5 2018-10-11
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended

2023-506399-28-00 Crohn's Disease 5 2017-11-08
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple… Ended

2023-504951-29-00 Chron's Disease 5 2017-07-27
A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended

2022-502393-16-00 Moderately to Severely Active Ulcerative Colitis 5 2023-09-06
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
Clinical Outcomes, Tolerability and Safety of Oral Pantoprazole in Pediatric Participants Ended

2023-508770-28-00 EROSIVE ESOPHAGITIS 4 2021-10-05
A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan… Ended

2024-513569-38-00 Crohn's Disease 10 2021-07-09